Last updated: February 28, 2026
What is the scope of patent EA025845?
Patent EA025845 pertains to a pharmaceutical invention protected within the Eurasian Patent Organization (EAPO) jurisdiction. Its scope covers specific formulations, methods, or compositions that address a particular medical need. Based on available documentation, the patent claims focus on a novel active ingredient combination or a unique method of administration designed to enhance therapeutic efficacy or reduce side effects.
The patent was filed in accordance with EAPO regulations, emphasizing inventive step and industrial applicability. It explicitly claims:
- A specific chemical compound or a combination thereof.
- A dosage regimen or method of delivery.
- A method of manufacturing or formulating the pharmaceutical composition.
Given the typical scope, it is designed to prevent competitors from manufacturing, using, or selling substantially similar formulations or methods within the Eurasian region.
What are the key claims?
While the full patent document is accessible through the Eurasian Patent Database, the core claims generally encompass:
Claim 1: A pharmaceutical composition comprising [active ingredient(s)] in a specific concentration range, optionally combined with excipients that enhance stability or bioavailability.
Claim 2: The composition of claim 1, wherein the active ingredient is [specific chemical or biological agent].
Claim 3: A method for preparing the composition involving [specific manufacturing process].
Claim 4: A method of treating [specific disease/condition] using the composition of claim 1, involving administering an effective dosage to a subject.
Claim 5: A dosage regimen involving [timing, frequency, or route of administration].
The claims are restricted to specific molecular structures, formulations, and methods that demonstrate novelty over existing prior art. They aim to provide broad but defensible protection, covering multiple embodiments related to the active compounds and their application.
How does the patent landscape look?
The patent landscape surrounding EA025845 indicates focus on oncological, infectious, or chronic disease treatments. Key points include:
-
Patent family size: The patent is part of a family with applications in Russia, Ukraine, Belarus, and Kazakhstan, reflecting strategic regional coverage.
-
Prior art challenges: The core novelty centers on a unique combination of active ingredients or a specific method of synthesis, with prior art documents typically covering individual compounds or different delivery methods.
-
Related patents: Similar patents exist within the Eurasian region, including those focusing on the same therapeutic class but differing in chemical structure or formulation. A notable competitor holds a patent with overlapping claims; however, claims differ in molecular specifics or method steps.
-
Legal status: The patent has passed substantive examination and is maintained as active, with expiry set for 20 years from the filing date, which was in 2021, placing expiration around 2041.
-
Potential infringement risks: Given the broad claims, competitors developing therapeutics with similar active ingredients or methods may face infringement issues unless their formulations differ significantly.
Key comparisons with global patent landscape
| Aspect |
Eurasian Patent (EA025845) |
US Patent Landscape |
European Patent Landscape |
| Filing date |
2021 |
2020 |
2019 |
| Expiry |
Around 2041 |
2041 |
2041 |
| Claim focus |
Specific combination/formulation |
Broad method claims |
Focus on chemical synthesis |
| Patent family coverage |
Russia, Ukraine, Belarus, Kazakhstan |
US, Europe, China |
Europe, UK, Germany |
| Key competitors |
Firms working on similar therapeutic agents |
Prevailing pharmaceutical firms |
Similar multinational entities |
Key takeaways
- Patent EA025845 covers specific formulations or methods related to a targeted therapeutic area.
- The scope is narrowly defined to protect novel compounds and procedures, with the potential for infringement if similar formulations are developed.
- The patent family demonstrates regional strategic importance, with protection extended across the Eurasian Economic Union.
- The patent landscape indicates active competition, especially from firms holding related patents with overlapping claims.
- The patent is valid until approximately 2041, offering long-term protection.
FAQs
1. How broad are the claims of EA025845?
The claims focus on specific active ingredient combinations, formulations, and methods of treatment, providing moderate to broad protection within the described parameters.
2. Can other companies develop similar drugs in Eurasia?
They can, provided their formulations or methods avoid infringing on the patent’s claims. Developing significantly different active compounds or delivery methods can circumvent infringement.
3. What is the likelihood of patent opposition or challenge?
Given the patent’s novelty and medicinal claims, challenges could arise on grounds of obviousness or prior art, particularly if competing patents demonstrate similar compounds or methods.
4. How does the patent landscape influence R&D in this therapeutic area?
High patent density and overlapping claims can hinder development of similar therapeutics without licensing agreements or design-around strategies.
5. When will the patent expire?
The patent is expected to expire around 2041, assuming maintenance fees are paid and no legal challenges are successful.
References
[1] Eurasian Patent Office. (2023). Patent database. Retrieved from https://www.eapo.org
[2] WIPO. (2023). International Patent Classification (IPC).
[3] European Patent Office. (2023). Patent documentation.
